Company intelligence / Profile preview

Niadyne Pharma

Fort Worth, Texas, United Statesniadynepharma.com ↗

Ownership: Private
Development stage: Other

Overview

The lead program, myristyl nicotinate targeting HCAR3 x NIACR1, has reached a "pending" clinical stage for actinic keratosis and plaque psoriasis. No published clinical results or approvals as of June 2025.

Therapeutic areas: Dermatology
Modalities: Small moleculeTopical drug delivery
Industry: Biotech

Drug pipeline

2 assets

myristyl nicotinate

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Niadyne Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Niadyne Pharma.

Explore the full profile